Human apolipoprotein A-I

Unassigned

New Medicines

Acute coronary syndrome (ACS) in adults with STEMI or NSTEMI - first-line

Information

New molecular entity
CSL Behring
CSL Behring

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Human apoA-I selectively promotes cholesterol efflux from arterial wall macrophages via the ABCA1 transporter (ATP-binding cassette transporter A1), resulting in antiatherosclerotic effects
The overall incidence of myocardial infarction in England in 2010 was 154 per 100,000 in men and 34 per 100,000 in women [2].
Acute coronary syndrome (ACS) in adults with STEMI or NSTEMI - first-line
Intravenous